Dexmedetomidine for Laryngeal Mask Airway Insertion

Ajou University School of Medicine

Status and phase: Completed; Phase 4

Conditions: Drug Usage

Treatments: Drug: propofol; Device: laryngeal mask airway (LMA); Drug: dexmedetomidine

Study type: Interventional

Funder types: Other

Identifiers

NCT01852539

AJIRB-MED-CT4-13-045

Details and patient eligibility

About

The investigators attempted to determine the optimal dose of dexmedetomidine required for the successful insertion of LMA during propofol induction without a neuromuscular blocking agent.

Full description

After a predetermined bolus dose of dexmedetomidine was injected over 2 min, anesthesia was induced with propofol 2.0 mg/kg. After confirming the loss of eyelash reflex and the bispectral index (BIS) score decreased below 60, the insertion of LMA was attempted.

Enrollment: 22 patients

Sex: All

Ages: 18 to 60 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• ASA I-II patients undergoing general anesthesia for short elective surgery (<1 hr)

Exclusion criteria

• G-E reflux
• obesity (BMI>30)
• anticipated difficult airway

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: Double Blind

---

22 participants in 1 patient group

dexmedetomidine

Experimental group

Description:

After intravenous infusion of dexmedetomidine for 2 min, propofol 2.0 mg/kg was administrated. And laryngeal mask airway device was inserted(LMA # 3,4).

Treatment:

Drug: dexmedetomidine

Device: laryngeal mask airway (LMA)

Drug: propofol